相关实验视频
Updated: Jan 7, 2026

10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.6K
基于计算机断层扫描的双臂治疗计划在宫癌的剂量测量分析
Deepthi Valiyaveettil1, Swapna Jilla2, Ramakrishna Ketham2
1Department of Radiation Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
South Asian journal of cancer
|December 25, 2025
概括
基于计算机断层扫描 (CT) 扫描的支臂治疗 (BT) 是治疗局部晚期宫癌的有效和可访问的方法. 这种技术确保了应用器的准确放置,并优化了向有风险的目标区域和器官的辐射剂量传递.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 医学物理 医学物理
背景情况:
- 同时的化疗照射,其次是支臂疗法 (BT) 是局部晚期子宫癌的标准.
- 现在推图像引导的BT (IGBT),基于CT的BT是一个成本效益和可访问的选择.
- 这项研究旨在在宫癌患者中进行基于CT的BT的剂量分析.
研究的目的:
- 评估基于CT的支臂治疗 (BT) 对局部晚期宫癌的剂量参数.
- 评估CT引导的BT在优化辐射剂量传递方面的可行性和有效性.
- 分析剂量分布到高风险临床目标体积 (HRCTV) 和有风险的器官 (OAR).
主要方法:
- 对50名宫癌患者的回顾性分析,这些患者接受了激进化疗和BT治疗.
- 在每次BT分离之前,为规划和应用器放置的验证,获得了CT扫描.
- 剂量计数据,包括每小部分2Gy的总相当剂量 (EQD2),收集并分析了目标体积和OARs.
主要成果:
- 该研究包括50名患者,主要是III期,平均年龄为45岁.
- 平均高风险临床目标体积 (HRCTV) 在分数中略有下降.
- 平均D90 HRCTV剂量为81.4Gy (EQD2 10Gy),直肠/阴茎的D2cc剂量为75.8Gy (EQD2 3Gy),膀的D2cc剂量为86.2Gy (EQD2 3Gy).
结论:
- 基于CT的BT是治疗宫癌的可行和经济有效的选择,特别是在资源有限的环境中.
- 在每个分数中实施基于CT的BT可方便应用器的精确放置和剂量优化.
- 这种方法有助于通过确保精确的辐射输送来改善局部控制和生存结果.
相关概念视频
Computed Tomography
7.9K
Tomography refers to imaging by sections. Computed tomography (CT) is a non-invasive imaging technique that uses computers to analyze several cross-sectional X-rays to reveal minute details about structures in the body.
The technique was invented in the 1970s and is based on the principle that as X-rays pass through the body, they are absorbed or reflected at different levels. In the technique, a patient lies on a motorized platform while a computerized axial tomography (CAT) scanner rotates...
The technique was invented in the 1970s and is based on the principle that as X-rays pass through the body, they are absorbed or reflected at different levels. In the technique, a patient lies on a motorized platform while a computerized axial tomography (CAT) scanner rotates...
7.9K
Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626

